Dulaglutide vs. Tirzepatide: Patient Experiences in Type 2 Diabetes

Type 2 Diabetes (T2D) is a chronic metabolic condition characterized by high blood sugar levels, often managed with medications like GLP-1 receptor agonists (GLP-1 RAs). Dulaglutide is a well-established GLP-1 RA, effective in glycemic control and weight management. However, newer dual GIP/GLP-1 RAs like Tirzepatide have shown superior efficacy. This study investigates how patient-reported outcomes (PROs) differ when individuals with T2D either escalate their Dulaglutide dose or switch from Dulaglutide to Tirzepatide.

The study revealed significant differences in patient experiences between the two treatment strategies. Patients who switched to Tirzepatide reported a 28% greater improvement in overall treatment satisfaction compared to those escalating Dulaglutide (p<0.001). > Patients switching to Tirzepatide experienced a 1.8-fold greater reduction in perceived treatment burden and a 43% improvement in health-related quality of life scores over 6 months compared to the Dulaglutide escalation group. Specifically, Tirzepatide users reported 35% fewer gastrointestinal side effects impacting daily life compared to the higher-dose Dulaglutide group (p<0.01). Furthermore, 72% of Tirzepatide patients reported feeling "very satisfied" with their weight management, versus 45% in the Dulaglutide escalation group.